←
Daniel Castellano9,550 posts
Daniel Castellano avatar✓

Daniel Castellano ✓

@cdanicas

Medical Oncologist. Hospital Univ. 12 de Octubre. Madrid. UCM. Head GU Unit. Executive Member @GUARDconsortitum

◷ Joined January 2013▧ 629 Photos and videos
GUARD Consortium avatar
⟳ Daniel Castellano retweeted
GUARD Consortium@GuardConsortium·Nov 17

🧔 MOVEMBER | TIP DE INVESTIGACIÓN Al evaluar programas de detección del cáncer de próstata, no basta con mirar la prueba: también importan la identificación de la población, la información, el seguimiento y la calidad del programa. La IARC analizó estos requisitos en pilotos europeos: iarc.who.int/news-events/map… #Movember #CáncerDePróstata #Investigación @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1

Post attachment
FLoscoMD avatar
⟳ Daniel Castellano retweeted
FLoscoMD@fedelosco·21h

🇦🇷 At #ESMOAI2026 in Berlin, we shared our survey of 181 people with cancer in Argentina. 46% had used generative AI for cancer-related questions. Only 40% of those users had discussed it with their doctor. Do we ask our patients about their AI use? @myESMO @aaoncoclinica

Post attachment
Niklas Klümper avatar
⟳ Daniel Castellano retweeted
Niklas Klümper@niklas_kluemper·Nov 10

🚀 What if a simple blood draw could reveal not only tumor burden, but also PSMA expression, tumor lineage and emerging resistance? Super exciting #ESMO2026 data! 🧬 Comprehensive plasma epigenomic profiling from just 1 mL of plasma in mCRPC patients receiving ¹⁷⁷Lu-PSMA-617. 🔬 57 patients, 77 plasma samples 🎯 Plasma-derived PSMA estimates correlated with PSMA-PET and clinical outcomes 📉 At progression, predicted PSMA expression declined in 11/17 paired patients 🔄 Alternative targets, including TROP2 and STEAP1, were frequently retained or increased! Particularly fascinating: Plasma profiling identified distinct AR-driven, stem/EMT and proliferative tumor states associated with treatment outcomes. From liquid biopsy to functional tumor phenotyping—without another tissue biopsy! Could this technology eventually guide radioligand therapy selection and subsequent ADC sequencing? Important caveat: Exploratory congress data. Predicted target expression is not yet a clinically validated substitute for PET imaging or tissue assessment. #ProstateCancer #Theranostics #LiquidBiopsy @OncoAlert @weoncologists @urotoday @Uromigos @OncoAlert and Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3

Post attachmentPost attachment
GUARD Consortium avatar
⟳ Daniel Castellano retweeted
GUARD Consortium@GuardConsortium·Nov 12

🎥 CÁPSULA GUARD | Biomarcadores en tumores urológicos BRCA y FGFR, entre otros biomarcadores, forman parte de la conversación sobre cómo trasladar el conocimiento molecular a la práctica clínica. Descubre la cápsula del Dr. Nil Navarro 🎬 guardconsortium.org/investig… #Biomarcadores #OncologíaGU #GUARDConsortium @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1

Post attachment
Niklas Klümper avatar
⟳ Daniel Castellano retweeted
Niklas Klümper@niklas_kluemper·Nov 11

🎯 ADC targets are not necessarily stable! Exciting new UTUC study (n=141): Membranous NECTIN4 positivity: 🔹 Chemo-naive: 47% 🔹 Chemo-exposed: 9.3% TROP2 positivity: 🔹 Chemo-naive: 100% 🔹 Chemo-exposed: 97% Could prior chemotherapy reshape the ADC target landscape? Important implications for EV resistance and subsequent ADC sequencing! Target expression matters. Timing and tissue context may matter just as much. 🔬 @OncoAlert @weoncologists @urotoday @Uromigos @OncoAlert and Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3

Post attachmentPost attachment
David Lorente avatar
⟳ Daniel Castellano retweeted
David Lorente@Dav_Lorente·Nov 9

1/9 Our latest manuscript from the #CAPTURE platform in advanced #ProstateCancer is published in @EurUrolOncol. The prognostic impact of BRCA2 gene alterations has been well established, but is BRCA1 comparable to BRCA2? Are all non-BRCA HRR alterations equivalent? 🧵

Post attachment